A Comparative Trial of Salazopyrin Prednisone and Hydrocortisone Retention Enemata in the Out-Patient Treatment of Left-Sided Colitis. Preliminary Report

Lennard‐Jones, J. E.; Longmore, Avery; Jones, F. Avery

doi:10.1177/003591576005300817

Cited by 8 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study nausea, headache, and abdominal discomfort were the most frequent symptoms reported by the subjects and they are common symptoms registered for patients on sulphasalazine therapy (Svartz, 1942;Lagercrantz, 1949;Morrison, 1952;Moertel and Bargen, 1959;Lennard-Jones et al, 1960;Watkinson, 1961;Baron et al, 1962;Truelove et al, 1962;Dick et al, 1964;Misiewicz et al, 1965;Collins, 1968). Nausea and headache are common symptoms also for patients on sulphapyridine therapy (Hawking and Lawrence, 1950).…”

Section: Discussionmentioning

confidence: 65%

Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects

Schröder¹,

Evans²

1972

Gut

101

View full text Add to dashboard Cite

SUMMARY Sulphasalazine (salicyl-azo-sulphapyridine) was ingested by 27 healthy subjects for five days at a dosage of 4 g daily. The acetylator phenotype of each subject had been established previously. The serum concentrations of the parent drug and its sulphapyridine-metabolites were determined and the adverse effects were recorded. There was no correlation between the serum concentrations of sulphasalazine and the adverse effects. The slow acetylators obtained enhancement of serum concentrations of sulphapyridine earlier than the rapid acetylators. They also reported adverse effects earlier and of more pronounced nature than the rapid acetylators. The data as a whole suggest that the adverse effects observed were caused by the metabolite sulphapyridine and that they are influenced by the polymorphic acetylation.Sulphasalazine (salicyl-azo-sulphapyridine) was first used in the treatment of ulcerative colitis by Svartz (1942). Controlled studies have demonstrated the clinical efficacy of the drug in mild and moderate cases of ulcerative colitis (Baron, Connell, LennardJones, and Avery Jones, 1962;Dick, Grayson, Carpenter, and Petrie, 1964). It has also been shown that the relapse rate is reduced upon sulphasalazine therapy (Misiewicz, Lennard-Jones, Connell, Baron, and Avery Jones, 1965). The use of the drug is, however, somewhat marred by adverse effects such as nausea, headache, abdominal discomfort, and malaise (

show abstract